Abstract 1994: Integrative multi-omic analysis reveals subtype-specific impact of extrachromosomal DNA in melanoma.

Abstract Extrachromosomal DNA (ecDNA) drives oncogene amplification, transcriptional deregulation, and therapeutic resistance in cancer, but its prevalence and impact in melanoma remain unclear. We analyzed 470 TCGA-SKCM samples with whole-genome (n = 223), whole-exome (n = 247), and RNA sequencing (n = 469). Tumors were classified as BRAF/NRAS/NF1-mutant (BNN, n = 396) or triple wild-type (TWT, n = 74). ecDNA detection was performed using AmpliconArchitect (AA) and Gene-level Circular Amplicon Prediction (GCAP). Multi-omic analyses assessed transcriptional, immunologic, and clinical correlates. ecDNA was detected in 133 tumors (28%; 47 by AA, 133 by GCAP, 39 overlapping), with higher prevalence in TWT tumors (51%) than BNN tumors (26%; χ2 = 17.88, p = 2.4 × 10−5). Frequently amplified ecDNA genes included MDM2, CDK4, CCND1, BIRC2/3, PAK1, GAB2, and RSF1, implicating proliferation, apoptosis evasion, and chromatin regulation. In an effort to assess putative functional impact, we performed various transcriptomic analyses which identified upregulation of amplified oncogenes (GAB2, MDM2, RSF1, CCND1, PAK1). In addition, gene set enrichment analyses with MutSigDB (against Hallmark genes) shows strong enrichment of pathways associated with enhanced cell proliferation, such as MYC and E2F targets in ecDNA+ tumors. In addition, cell deconvolution methods reveal immune cell composition varies across subtypes, highlighting potential unique immunomodulatory effects. Survival analysis indicated worse overall survival in ecDNA+ tumors (p = 0.016), driven by TWT cases (p = 0.0048). ecDNA is prevalent in melanoma, particularly in TWT tumors, where it promotes oncogene amplification, immunomodulatory reprogramming, and poor prognosis. These results highlight ecDNA as a potential biomarker for stratification and targetable vulnerability in TWT melanoma. Citation Format: Sharadha Sakthikumar, Bryce Turner, Jeffrey Trent, ALEKSANDAR SEKULIC. Integrative multi-omic analysis reveals subtype-specific impact of extrachromosomal DNA in melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1994.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-1994
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 1994: Integrative multi-omic analysis reveals subtype-specific impact of extrachromosomal DNA in melanoma.

Sharadha Sakthikumar, Jeffrey M. Trent, Bryce Turner, ALEKSANDAR SEKULIC
Cancer Research
Cancer Genomics and Diagnostics
article

Abstract 1994: Integrative multi-omic analysis reveals subtype-specific impact of extrachromosomal DNA in melanoma.

Sharadha Sakthikumar, Jeffrey M. Trent, Bryce Turner, ALEKSANDAR SEKULIC
article en

Abstract

Abstract Extrachromosomal DNA (ecDNA) drives oncogene amplification, transcriptional deregulation, and therapeutic resistance in cancer, but its prevalence and impact in melanoma remain unclear. We analyzed 470 TCGA-SKCM samples with whole-genome (n = 223), whole-exome (n = 247), and RNA sequencing (n = 469). Tumors were classified as BRAF/NRAS/NF1-mutant (BNN, n = 396) or triple wild-type (TWT, n = 74). ecDNA detection was performed using AmpliconArchitect (AA) and Gene-level Circular Amplicon Prediction (GCAP). Multi-omic analyses assessed transcriptional, immunologic, and clinical correlates. ecDNA was detected in 133 tumors (28%; 47 by AA, 133 by GCAP, 39 overlapping), with higher prevalence in TWT tumors (51%) than BNN tumors (26%; χ2 = 17.88, p = 2.4 × 10−5). Frequently amplified ecDNA genes included MDM2, CDK4, CCND1, BIRC2/3, PAK1, GAB2, and RSF1, implicating proliferation, apoptosis evasion, and chromatin regulation. In an effort to assess putative functional impact, we performed various transcriptomic analyses which identified upregulation of amplified oncogenes (GAB2, MDM2, RSF1, CCND1, PAK1). In addition, gene set enrichment analyses with MutSigDB (against Hallmark genes) shows strong enrichment of pathways associated with enhanced cell proliferation, such as MYC and E2F targets in ecDNA+ tumors. In addition, cell deconvolution methods reveal immune cell composition varies across subtypes, highlighting potential unique immunomodulatory effects. Survival analysis indicated worse overall survival in ecDNA+ tumors (p = 0.016), driven by TWT cases (p = 0.0048). ecDNA is prevalent in melanoma, particularly in TWT tumors, where it promotes oncogene amplification, immunomodulatory reprogramming, and poor prognosis. These results highlight ecDNA as a potential biomarker for stratification and targetable vulnerability in TWT melanoma. Citation Format: Sharadha Sakthikumar, Bryce Turner, Jeffrey Trent, ALEKSANDAR SEKULIC. Integrative multi-omic analysis reveals subtype-specific impact of extrachromosomal DNA in melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1994.

Cancer ResearchVol. 86(7_Supplement)
Translational Genomics Research Institute (US)
Openalex Percentile: Top 10%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.